Reversal of multidrug resistance by a liposome- MDR 1 ribozyme complex

Masuda, Yoshihiro; Kobayashi, Hiroyuki; Holland, James F.; Ohnuma, Takao

doi:10.1007/s002800050778

Cited by 22 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other reports have proposed novel NP applications to reverse MDR, such as LAH4L1, an amphipathic cationic polypeptide, to form nanocomplexes via electrostatic interactions with siRNA to have high transfection efficiency in delivering siMDR1 to reverse MDR in ovarian cancer cells. 88 Other reports have reversed MDR using codelivery of MDR1-targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolic acid) (PLGA) nanoformulation, 89 formulating MDR1 ribozymes with N- (1-[2,3-dileoyloxy]propyl)-N,N,N-trimethylammonium methyl sulfate to form a liposomal complex, 90 and constructing a pDNA-iMDR1-shRNA containing a U6-RNA genepromoter-driven expression vector encoding anti-MDR1/ Pgp shRNA molecules. 91 Li et al 92 gave an essential detailed review on the recent developments on the application in PAMAM dendrimers as useful carriers for drug and genetic material (pDNA, siRNA) delivery in cancer therapy, as well as their use in hybrid NPs, and conjugated or loaded in other NP systems.…”

Section: Clinical Importance Of Smartnanoparticle Drug Deliverymentioning

confidence: 99%

Recent advances in "smart" delivery systems for extended drug release in cancer therapy

Kalaydina¹,

Bajwa

Qorri

et al. 2018

IJN

197

122

View full text Add to dashboard Cite

Advances in nanomedicine have become indispensable for targeted drug delivery, early detection, and increasingly personalized approaches to cancer treatment. Nanoparticle-based drug-delivery systems have overcome some of the limitations associated with traditional cancer-therapy administration, such as reduced drug solubility, chemoresistance, systemic toxicity, narrow therapeutic indices, and poor oral bioavailability. Advances in the field of nanomedicine include “smart” drug delivery, or multiple levels of targeting, and extended-release drug-delivery systems that provide additional methods of overcoming these limitations. More recently, the idea of combining smart drug delivery with extended-release has emerged in hopes of developing highly efficient nanoparticles with improved delivery, bioavailability, and safety profiles. Although functionalized and extended-release drug-delivery systems have been studied extensively, there remain gaps in the literature concerning their application in cancer treatment. We aim to provide an overview of smart and extended-release drug-delivery systems for the delivery of cancer therapies, as well as to introduce innovative advancements in nanoparticle design incorporating these principles. With the growing need for increasingly personalized medicine in cancer treatment, smart extended-release nanoparticles have the potential to enhance chemotherapy delivery, patient adherence, and treatment outcomes in cancer patients.

show abstract

Section: Clinical Importance Of Smartnanoparticle Drug Deliverymentioning

confidence: 99%

Recent advances in "smart" delivery systems for extended drug release in cancer therapy

Kalaydina¹,

Bajwa

Qorri

et al. 2018

IJN

197

122

View full text Add to dashboard Cite

show abstract

“…17 Stable transfectants generated using retroviral vectors that expressed ABCB1 ribozymes resulted in significantly decreased ABCB1 mRNA levels. 18 Reversal of cisplatin resistance by anti-ABCC2 hammerhead ribozymes was demonstrated in human cancer cells. 19 The expression of ABCC2 was specifically reduced by antisense DNA expressed from a CMV expression A 'multitarget multiribozyme' constructed that consisted of three hammerhead motifs directed against transcripts of ABCB1, BCRP and ABCC2 specifically reduced the corresponding transporter ABCB1, BCRP and ABCC2 in all cellular systems.…”

Section: Discussionmentioning

confidence: 99%

Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs

et al. 2007

View full text Add to dashboard Cite

Human cancers are characterized by a high degree of drug resistance. The multidrug resistance transporters MDR1-P-glycoprotein (ABCB1) and ABCC2 (MRP2) are expressed in a variety of human cancers, including hepatocellular carcinoma (HCC). The ABCC2 gene encodes a membrane protein involved in the ATP-dependent transport of conjugates of lipophilic substances. In this study we analyzed the effect of an ABCC2 antisense construct on the chemosensitization of HepG2 cells. Adenoviral vectors were constructed to allow an efficient expression of anti-ABCC2 antisense constructs. The effective target sequence comprised nucleotides 2543-2942 of the human ABCC2 cDNA. Adenoviral delivery of the ABCC2 antisense construct resulted in a reduced IC 50 for doxorubicin (12-fold), vincristine (50-fold), cisplatin (25-fold) and etoposide (VP-16) (25-fold). The adenoviral delivery of the ABCC2 antisense construct was so efficient that chemosensitization of HepG2 cells could even be demonstrated in mass cell cultures without a selection of transduced cells for single ABCC2 antisense-expressing HCC cell clones. After transfection of the ABCC2 antisense-expressing construct, HepG2 cells had significantly reduced ABCC2 mRNA and ABCC2 protein levels. Transduction of the ABCC2 antisense-expressing construct into HepG2 cells resulted in the accumulation of the high-affinity ABCC2 substrate Fluo-3. HepG2 tumors stably transfected with an anti-ABCC2 antisense construct regressed significantly in nude mice upon vincristine treatment. In addition, significant tumor regression was also observed when adenovirus-expressing anti-ABCC2 antisense construct was directly injected into HepG2 tumors in nude mice. Our study demonstrates the specific reversal of ABCC2-related drug resistance in adenovirus-transduced HepG2 cells and in HepG2 tumors in nude mice expressing this ABCC2 antisense construct.

show abstract

“…Ribozymes are small RNA molecules (30-40 nucleotides) that hybridize to a complementary sequence of mRNA and catalyze site-specific cleavage of the substrate. Anti-MDR ribozymes, introduced into the cells, can reverse MDR by cleavage of MDR1 and MRP mRNA (Masuda et al, 1998;Kobayashi et al, 1999;Wang et al, 1999;Nagata et al, 2002;Wang et al, 2003).…”

Section: Control Of Expression Of Mdr Proteinsmentioning

confidence: 99%

Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells.

Borowski¹,

Bontemps-Gracz²,

Piwkowska³

2005

Acta Biochim Pol

112

View full text Add to dashboard Cite

The development of multidrug resistance (MDR) of tumors is a major cause of failure in antitumor chemotherapy. This type of cross-resistance is due to the expression of ABC transporter glycoproteins actively effluxing the drug from the cells against the concentration gradient at the expense of metabolic energy, thus preventing the accumulation in cells of therapeutic concentration of active agents. In this review strategies for overcoming this adverse phenomenon are discussed. They comprise the control of expression of MDR glycoprotein transporters and control of the functioning of the expressed transporter proteins. The latter approach is discussed in more detail, comprising the following general strategies: (i) development of compounds that are not substrates of efflux pump(s), (ii) use of agents that inactivate (inhibit) MDR proteins, (iii) design of cytostatics characterized by fast cellular uptake, surpassing their mediated efflux, (iv) use of compounds competing with the drug for the MDR protein-mediated efflux. Positive and negative aspects of these strategies are analysed, with special attention put on strategy based on the use of MDR modulators in combination therapy, allowing the restoration of cytotoxic activity of clinical cytostatics towards resistant tumor cells.

show abstract

Reversal of multidrug resistance by a liposome- MDR 1 ribozyme complex

Abstract: Endocytotic activity was correlated with the success of cationic liposome-mediated transfer of MDR1 ribozyme. Determination of endocytotic activity of target tumor cells may be predictive of efficacy of liposome-mediated gene transfer.

Cited by 22 publications

References 16 publications

Recent advances in "smart" delivery systems for extended drug release in cancer therapy

Recent advances in "smart" delivery systems for extended drug release in cancer therapy

Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs

Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells.

Contact Info

Product

Resources

About

Reversal of multidrug resistance by a liposome- MDR 1 ribozyme complex

Abstract: Endocytotic activity was correlated with the success of cationic liposome-mediated transfer of MDR1 ribozyme. Determination of endocytotic activity of target tumor cells may be predictive of efficacy of liposome-mediated gene transfer.

Cited by 22 publications

References 16 publications

Recent advances in &quot;smart&quot; delivery systems for extended drug release in cancer therapy

Recent advances in &quot;smart&quot; delivery systems for extended drug release in cancer therapy

Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs

Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells.

Contact Info

Product

Resources

About

Recent advances in "smart" delivery systems for extended drug release in cancer therapy

Recent advances in "smart" delivery systems for extended drug release in cancer therapy